<font size=2 face="sans-serif">fyi:</font>
<br>
<br><font size=2 face="sans-serif"><snip></font>
<br><font size=3 face="Times New Roman">I would like to inform you of some
exciting news regarding Aperio and Leica Biosystems.</font>
<br><font size=3 face="Times New Roman"> </font>
<br><font size=3 face="Times New Roman">Today it was announced that Leica
Biosystems will acquire Aperio as a major initiative in growing its digital
pathology capabilities.</font>
<br><font size=3 face="Times New Roman"> </font>
<br><font size=3 face="Times New Roman">Aperio is by far the largest solution
provider to Life Sciences and Healthcare for digital scanning equipment
and software platforms for the management of ePathology data and image
analysis. The combination of Leica’s laboratory pathology’s capabilities,
including advanced reagents and staining equipment together with Aperio’s
digital slide and analysis capabilities provides a strong end to end solution
for research and clinical laboratories.</font>
<br><font size=3 face="Times New Roman"> </font>
<br><font size=3 face="Times New Roman">Increasingly Aperio’s ePathology
Solutions, including Telepathlogy and PRECISION Analytics are taking a
central role in biomarker development by facilitating a collaborative GxP
compliant platform between organizations, which speeds the delivery of
personalized healthcare. The ability of Pharma’, CRO’s, reagent companies
and other collaborating organizations to work within an integrated pathology
environment</font>
<br><font size=3 face="Times New Roman">is a major step forward.</font>
<br><font size=3 face="Times New Roman"> </font>
<br><font size=3 face="Times New Roman">This acquisition as truly exciting
for both the Life Science and Healthcare Divisions of Aperio. If you have
any questions please do not hesitate to contact me,</font>
<br><font size=3 face="Times New Roman"> </font><font size=2 face="sans-serif"></snip></font>
<br><HR><BR>WARNING: This e-mail, including any attachments, may contain CONFIDENTIAL INFORMATION, including privileged and/or health information. It is for the sole use of the intended recipients. Any unauthorized copying, disclosure, distribution, reproduction, use or retention of this email or the information in it, is strictly FORBIDDEN. If you are not an intended recipient, please notify the sender immediately (REPLY this e-mail) and permanently DELETE the related e-mail. Please be aware that this email and replies to it may be monitored by the sender's company for quality assurance, policy compliance and/or security purposes.
<br>